Page 5 - reflections_newsletter10

REFLECTIONS
Dyslipidaemia
Dyslipidaemia Global Newsletter #10 2025

reduction. If statin response is incomplete, or if statin intolerance prevents achieving therapeutic objectives, these non-statin options
may also be used as monotherapy, as each has demonstrated ASCVD risk reduction in randomised clinical trials. Dyslipidaemia

Non-statin therapies, their anticipated reduction in LDL-C, and their impact on MACE in RCTs

While LDL-C remains the primary target, non-HDL-C
and apolipoprotein B (apoB) should also be considered
as secondary targets, especially in patients with
hypertriglycerideamia, diabetes, or obesity, as these markers
better capture the total burden of atherogenic particles. The
authors also note the emergence of long-acting ribose nucleic
acid (RNA)-based therapies, such as inclisiran, and future
gene-editing approaches that could offer durable control of
atherogenic lipoproteins and address adherence barriers.

Integrating complex guidance into a unified, simplified
framework is expected to improve clarity for providers, enhance CLICK HERE
patient understanding, and reduce variation in care. The authors VIEW AN EPISODE FROM THE LIPID
highlight that the most important clinical takeaway is the clear, INSIGHTS PODCAST HOSTED BY THE
actionable message: “lower for longer is better.” Clinicians NLA WITH DR. JACKSON AND DR.
should individualise LDL-C targets according to each patient’s WILLARD ON THIS PAPER. (36:32)
risk, ranging from <100 mg/dL for healthy adults to <30 mg/dL
for those at extreme risk, while reinforcing lifestyle modification
at every visit. Team-based care, including pharmacists, nurses, CLICK HERE
and when appropriate, referral to a lipid specialist, is key to FOR THE LINK TO FULL ARTICLE
sustaining LDL-C control and long-term ASCVD prevention.

TABLE OF CONTENTS